Zusammenfassung
Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Erkrankungen. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bristow MR (2000): β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569.
Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38:199–204.
Brodde OE (1991): Beta 1-and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.
Chobanian AV, Bakris GL, Black HR, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Hypertension 42:1206–1252. http://www.nhlbi.nih.gov/guidelines/hypertension/.
CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13.
Dargie HJ (2003): β-Blockers in heart failure. Lancet 362:2–3.
Deutsche Liga zur Bekämpfung des hohen Blutdrucks/Deutsche Hochdruckliga (2003): Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. http://www.paritaet.org/hochdruckliga/Leit2003.htm.
Eschenhagen T (2004): Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Heidelberg New York, S. 223–258.
Frishman WH, Kostis J, Strom J, Hossler M, Ekayam U et al (1979): Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6: A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535.
Ijzerman AP, Soudijn W (1989): The antiarrhythmic properties of β-adrenoceptor antagonists. Trends Pharmacol Sci 10:31–36.
Kilbinger H, Rahn K-H (2004): Hypertonic In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Berlin Heidelberg New York, S. 209–226.
Meier K, Lemmer B (2004): Blood pressure and heart rate after metoprolol or nebivolol and effects on nitric oxide urinary excretion in spontaneously hypertensive rats with and without 1-NAME. Z Kardiol/Germ J Cardiol 93(Suppl 3): P1320.
MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353:2001–2007.
Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658.
Pesant Y, Marc-Aurele J, Bielmann P, Alaupovic P, Cartier P, Bichet D, et al (1999): Metabolic and antihypertensive effects of nebivolol and atenolol in normome-tabolic patients with mild-to-moderate hypertension. Am J Ther 6:137–147.
Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001): Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19:1429–1435.
Poole-Wilson PA, Svedberg K, Geland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of Carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13.
Poynard T, Calés P, Pasta L, Ideo G, Pascal J-P et al and the Franco-Italian Multi-center Study Group (1991): Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 324:1532–1538.
Quyyumi AA, Wright C, Mockus L, Fox KM (1984): Effect of partial agonist activity in β-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol. Brit Med J 289: 951–953.
Ruf G, Trenk D, Jahnchen E, Roskamm H (1994): Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 43: 279–285.
Schrör K, Kelm M (2004): Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 259–275.
Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomised, double-blind, crossover study. Circulation 104: 511–514.
Van Nueten L, Taylor FR, Robertson JI (1998): Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 12: 135–140.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lemmer, B. (2004). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-18513-7_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21359-8
Online ISBN: 978-3-642-18513-7
eBook Packages: Springer Book Archive